Axsome Therapeutics, Inc. (AXSM) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-23

Key Insights

Chief Operating Officer Mark Jacobson acquired 8,669 performance stock units (PSUs) on 04/21/2026, representing contingent rights to receive common stock upon achievement of sales and commercial launch milestones.
The PSU grant is milestone-based rather than time-based vesting, indicating the company is tying executive compensation directly to commercial execution and product launch success.
This acquisition by a senior executive at a biotechnology company suggests confidence in upcoming commercial milestones and product launches, though the vesting is contingent on continued service.
The transaction occurred on 04/21/2026 with filing on 04/23/2026, showing standard regulatory compliance with no Rule 10b5-1 trading plan notation, indicating this was likely a routine equity grant rather than discretionary trading.

Want the newest filings?

This analysis covers the filing from 2026-04-23. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-23

CEO Herriot Tabuteau acquired 24,081 Performance Stock Units (PSUs) on 04/21/2026, representing contingent rights to common stock that vest upon achievement of sales and commercial launch milestones.
The PSU grant demonstrates management's confidence in Axsome's commercial prospects and ability to hit revenue targets, as vesting is tied to specific sales milestones rather than time-based vesting.
As both Director, 10% Owner, and CEO, Tabuteau's significant equity stake aligns his personal interests with shareholder value creation and successful product commercialization.

Filed: 2026-04-23

Chief Commercial Officer Ari Maizel exercised 7,500 stock options at $70.73 per share and immediately sold all 7,500 shares at an average price of $182.42, realizing a substantial gain of approximately $835,175 or 157% profit within the same day.
The transaction was executed under a pre-approved Rule 10b5-1 trading plan, indicating this was a planned, systematic transaction rather than a reactive market decision, which reduces concerns about negative insider sentiment.
After the sale, Maizel retains 23,710 shares of direct beneficial ownership, demonstrating continued meaningful equity stake in the company despite the full liquidation of this particular option exercise.
The significant gap between the exercise price ($70.73) and sale price ($182.42) suggests substantial stock appreciation since the options were granted, reflecting positive company performance or market conditions.

Filed: 2026-04-23

Chief Commercial Officer Ari Maizel received 7,224 Performance Stock Units (PSUs) on 04/21/2026, contingent upon achievement of sales and commercial launch milestones, indicating confidence in upcoming product commercialization targets.
The PSU grant is tied to specific performance metrics rather than automatic vesting, suggesting management's compensation is directly aligned with company's commercial execution and revenue generation goals.
This executive compensation structure demonstrates the company's focus on near-term commercialization success, particularly relevant given Maizel's role as Chief Commercial Officer overseeing market launch and sales efforts.

Filed: 2026-04-23

CFO Nick Pizzie acquired 8,188 performance stock units (PSUs) on 04/21/2026, representing contingent rights to common shares with $0 exercise price, indicating a compensation award rather than open market purchase.
PSU vesting is contingent upon achievement of sales and commercial launch milestones combined with continued service, suggesting management's compensation is directly tied to commercialization success of company products.
The grant of PSUs to the CFO signals confidence in upcoming revenue-generating milestones and product launches, though the contingent nature means these shares have not yet been earned.

Filed: 2026-04-23

Hunter Murdock, General Counsel of Axsome Therapeutics, acquired 7,224 performance stock units (PSUs) on April 21, 2026, representing a contingent right to receive common shares upon achievement of sales and commercial launch milestones.
The PSU grant is contingent on specific business milestones rather than time-based vesting, indicating management confidence in upcoming product commercialization or sales targets for the company's pipeline.
As General Counsel and an officer, Murdock's acceptance of milestone-based equity compensation suggests alignment with company growth objectives, though the zero upfront value indicates these are future-conditional awards rather than immediate wealth transfers.

Filed: 2026-02-10

The reporting person, Mark Coleman, exercised 5,193 stock options at $8.02 per share, indicating an increase in his direct ownership of Axsome Therapeutics' common stock.
Coleman also holds 403,856 shares indirectly through an entity over which he has voting and dispositive power, suggesting he maintains a significant ownership stake in the company.
The exercise of options and holding of the underlying shares signals the reporting person's confidence in Axsome Therapeutics' long-term prospects.

Filed: 2026-01-23

The reporting person, Nick Pizzie, who is the Chief Financial Officer of Axsome Therapeutics, Inc., exercised 12,000 stock options and immediately sold the underlying shares for a total transaction value of around $2.25 million.
The transaction was executed pursuant to a pre-approved 10b5-1 trading plan, indicating pre-planned portfolio management rather than a one-off transaction.
The reporting person continues to hold a direct ownership stake of 42,588 shares in the company, in addition to an indirect ownership of 488 shares held in custodial accounts for his children.

Filed: 2026-01-23

Ari Maizel, the Chief Commercial Officer of Axsome Therapeutics, Inc., exercised 7,500 stock options and subsequently sold the same number of shares on January 21, 2026.
The stock option exercise price was $70.73 per share, while the sale price was a weighted average of $184.44 per share, suggesting a significant gain for the reporting person.
This transaction was conducted pursuant to a pre-approved 10b5-1 plan, indicating a planned and structured approach to the insider's trading activity.

Filed: 2026-01-07

Axsome Therapeutics' CEO Herriot Tabuteau exercised and sold a significant number of stock options in early January 2026, indicating insider selling activity.
The sales were executed pursuant to a pre-approved 10b5-1 trading plan, suggesting a planned and systematic liquidation of Tabuteau's equity holdings.
Tabuteau also holds a large indirect beneficial ownership stake in Axsome, suggesting he maintains a substantial economic interest in the company.

Other reports for Axsome Therapeutics, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.